今天和未来对新诊断的多发性骨髓瘤的管理
Anup Joseph Devasia1, Guido Sebastian Lancman1, Alexander Keith Stewart1
1Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, 700 University Avenue, Toronto, Ontario, M5G 1X6 Canada.
在过去的20年里,新的疗法改变了多发性骨髓瘤的治疗方法. 三倍和四倍疗法,包括单克隆抗体,改善了患者的反应,新的细胞疗法准备进一步推进治疗.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 多发性骨髓瘤的治疗在过去二十年里有了显著的进化.
- 基于三重新药的诱导疗法现在是全球标准,适用于移植和非移植的患者.
- 进步包括将抗CD38单克隆抗体整合到四重方案中.
研究的目的:
- 审查过去20年多发性骨髓瘤治疗的进展.
- 突出基于新型药物治疗方案和免疫疗法的影响.
- 讨论新兴疗法及其潜在的未来影响.
主要方法:
- 审查最近的临床试验和治疗指南.
- 从新型治疗方法中分析应答率和生存数据.
- 评估三倍和四倍疗程的疗效.
主要成果:
- 三组新药疗法已成为全球标准的诱导疗法.
- 四重组疗法,包括抗CD38单克隆抗体,实现更深入,更持久的反应.
- 这些四重组疗法在现有情况下已经证明了改变实践的结果.
结论:
- 目前多发性骨髓瘤的治疗模式已被新药和抗体疗法显著改善.
- 新兴疗法,如仿真抗原受体T细胞疗法和双特异性抗体,显示出前期治疗的前景.
- 这些创新方法有可能彻底改变新诊断的多发性骨髓瘤的管理.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
相关概念视频
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
